<DOC>
	<DOCNO>NCT00480324</DOCNO>
	<brief_summary>This study undertaken provide regulatory authority Japan immunogenicity , efficacy , safety reactogenicity data GSK Biologicals ' Human Rotavirus [ HRV ] vaccine , give 2-dose primary vaccination , healthy Japanese infant age approximately 2 month time first dose previously uninfected HRV . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Efficacy , Safety , Reactogenicity &amp; Immunogenicity Rotarix Vaccine Japanese Infants</brief_title>
	<detailed_description>Combined diphtheria tetanus toxoid acellular pertussis ( DTPa ) Hepatitis B ( HBV ) vaccine allow co-administered along Rotarix vaccine/Placebo .</detailed_description>
	<mesh_term>Rotavirus Infections</mesh_term>
	<criteria>Healthy male female infant , include , 6 14 week ( 42104 day ) age time first vaccination . Subjects investigator believe parents/guardians comply requirement protocol enrol study Healthy subject establish medical history clinical examination enter study . Written inform consent obtain parent guardian subject . Born gestation period 36 42 week inclusive . Use investigational nonregistered product ( drug vaccine ) HRV vaccine within 30 day precede first dose HRV vaccine , plan use study period . History use experimental rotavirus vaccine . Chronic administration immunosuppressant immunemodifying drug since birth . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Uncorrected congenital malformation ( Meckel 's diverticulum ) gastrointestinal tract would predispose intussusception . Any clinically significant history chronic gastrointestinal disease include uncorrected congenital malformation gastrointestinal tract serious medical condition determine investigator . History allergic disease reaction likely exacerbate component vaccine . Previous confirm occurrence RV GE . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination ( laboratory testing require ) . A family history congenital hereditary immunodeficiency . Acute disease time enrolment . Gastroenteritis within 7 day precede study vaccine administration . Administration immunoglobulins and/or blood product since birth plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>14 Weeks</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>